Imaging Diagnostic Systems, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Private equity financing provides $25 mil. funding commitment from an institutional investor. The developer of the CTLM laser-based breast imaging device, designed to aid in the diagnosis of breast abnormalities without using breast compression or x-rays, plans to use the proceeds from the financing "for the ongoing clinical programs, product development, working capital and general corporate purposes," the firm states. The device utilizes laser technology and computed algorithms that create "contiguous cross-sectional slice images of the breast." Data from ongoing clinical trials at two sites are to be submitted to FDA in "late summer or early this fall," IDS says. The funding commitment provides the flexibility to draw upon the capital when needed, the firm notes
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.